- Home
- PMEC vs LSTA Comparison
PMEC vs LSTA Comparison
Compare PMEC & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- LSTA
- Stock Information
- Founded
- PMEC 1984
- LSTA 1980
- Country
- PMEC Singapore
- LSTA United States
- Employees
- PMEC N/A
- LSTA N/A
- Industry
- PMEC
- LSTA Misc Health and Biotechnology Services
- Sector
- PMEC
- LSTA Health Care
- Exchange
- PMEC Nasdaq
- LSTA Nasdaq
- Market Cap
- PMEC 26.1M
- LSTA 24.2M
- IPO Year
- PMEC 2023
- LSTA N/A
- Fundamental
- Price
- PMEC $0.75
- LSTA $2.58
- Analyst Decision
- PMEC
- LSTA Strong Buy
- Analyst Count
- PMEC 0
- LSTA 1
- Target Price
- PMEC N/A
- LSTA $15.00
- AVG Volume (30 Days)
- PMEC 71.5K
- LSTA 19.6K
- Earning Date
- PMEC 12-31-2024
- LSTA 11-12-2024
- Dividend Yield
- PMEC N/A
- LSTA N/A
- EPS Growth
- PMEC N/A
- LSTA N/A
- EPS
- PMEC N/A
- LSTA N/A
- Revenue
- PMEC $72,524,000.00
- LSTA N/A
- Revenue This Year
- PMEC N/A
- LSTA N/A
- Revenue Next Year
- PMEC N/A
- LSTA N/A
- P/E Ratio
- PMEC N/A
- LSTA N/A
- Revenue Growth
- PMEC 5.07
- LSTA N/A
- 52 Week Low
- PMEC $0.49
- LSTA $2.19
- 52 Week High
- PMEC $4.15
- LSTA $3.83
- Technical
- Relative Strength Index (RSI)
- PMEC 50.76
- LSTA 41.13
- Support Level
- PMEC $0.65
- LSTA $2.48
- Resistance Level
- PMEC $0.79
- LSTA $2.77
- Average True Range (ATR)
- PMEC 0.07
- LSTA 0.19
- MACD
- PMEC -0.01
- LSTA -0.01
- Stochastic Oscillator
- PMEC 43.78
- LSTA 56.52
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.